Armaviskon solution for intra-systemic administration. 1%, 2ml # 1 syringe

• to increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints;

• for rehabilitation after arthroscopy;

• for the treatment of patients with increased physical activity and regularly loading the affected joint.

Intra-articular. The contents of one filled syringe - 2 ml (20 mg) should be injected into the knee joint once a week, in a course of 5 injections according to the standard method described below. Typically a 1.5 '' 21G needle is used for the knee joint, for other joints it is recommended to use the correct size needle (17G to 22G) depending on the joint.

Method of introduction

The product should only be administered by trained medical personnel. The mode of introduction into the hip and other joints is determined by the doctor individually, taking into account the severity of degenerative or traumatic changes in the joint. It is recommended to perform injections into the hip and other joints under ultrasound or fluoroscopic guidance. It is recommended to warm the product to room temperature before use.

The agent should be injected exactly into the joint cavity according to standard techniques, taking into account the anatomical features. Before the introduction of the agent, the effusion should be removed from the joint capsule. The same needle, once inserted prior to aspiration, can be used to remove effusion and administer the agent.

In this case, the syringe with the agent is attached to the needle released from the syringe. To confirm that the needle is in the joint cavity, the available amount of synovial fluid should be aspirated before slow injection. You should follow the rules of asepsis and antiseptics when performing the procedure.

The introduction of the drug into the joint cavity should be stopped if pain occurs during the injection. When inserting a needle, especially for injections into the hip joint, the use of local anesthesia is recommended. Avoid getting air into the syringe. The product that has not been used up to the end cannot be stored. The duration of the therapeutic effect is up to 6 months. If necessary, it is possible to carry out a repeated course of injections after consulting a doctor.

Composition for 1 ml:

sodium hyaluronate - 9-11 mg / ml (1%),

sodium chloride - 8.50 mg / ml,

sodium hydrogen phosphate dihydrate - 0.28 mg / ml,

sodium dihydrogen phosphate dihydrate - 0.044 mg / ml,

water for injection - up to 1 ml.

• hypersensitivity to the components of the product;

• the presence of infection or damage to the skin in the area of ??injection;

• acute synovitis;

• children under 18 years of age (due to lack of clinical data).

pharmachologic effect

Applications - orthopedics, rheumatology, traumatology, surgery, sports medicine. The Armaviskon remedy is a protector of the synovial fluid of the joint. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore cartilage homeostasis.

Properties and efficiency

The tool has an analgesic, corrective effect on the metabolism of bone and cartilage tissue. Armaviskon is a sterile viscous solution of sodium salt of hyaluronic acid (sodium hyaluronate) of high purity, high molecular weight.

Hyaluronic acid, an essential component of the extracellular matrix, is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity to the synovial fluid and is essential for the formation of cartilage. In osteoarthritis, there is a deficiency and qualitative changes in hyaluronic acid in the synovial fluid and cartilage. Intra-articular administration of hyaluronic acid leads to an improvement in the functional state of the joint.

When using Armaviskon for osteoarthritis of the knee joint, there is an improvement in the clinical course of osteoarthritis 2 up to six months from the date of application, an anti-inflammatory and analgesic effect is observed due to volume replenishment and restoration of the viscosity and elasticity of the synovial fluid, which fills the joint cavity and acts as an intra-articular lubricant.

It prevents friction of the articular surfaces, which helps eliminate pain and inflammation. And also protects against premature wear and destruction of hyaline cartilage, provides mobility, has shock-absorbing ability (dampens external shocks, protecting the components of the joint from damage). A solution of sodium hyaluronate is distributed locally in the joint cavity, where it undergoes local transformations, providing a lubricating effect. Removal or replacement of the agent is not applicable, since it is inseparably mixed with the synovial fluid of the joint.

Side effects

Moderate pain, swelling, fever and redness in the injection area, and an increase in the exudate content in the joint cavity are possible.

The above symptoms are transient and usually disappear after 24 hours.

If these symptoms occur, it is recommended to relieve the affected joint and apply ice. Allergic reactions are extremely rare.

Interaction

Armaviskon should not be administered concurrently with other intra-articular injections, due to the lack of significant experience.

Disinfectants containing quaternary ammonium compounds should not be used as hyaluronic acid precipitates in the presence of these substances.